loading
Schlusskurs vom Vortag:
$8.71
Offen:
$8.7
24-Stunden-Volumen:
81,781
Relative Volume:
0.27
Marktkapitalisierung:
$416.72M
Einnahmen:
$36.90M
Nettoeinkommen (Verlust:
$-166.28M
KGV:
-2.652
EPS:
-3.29
Netto-Cashflow:
$-203.53M
1W Leistung:
+8.68%
1M Leistung:
+19.53%
6M Leistung:
-32.68%
1J Leistung:
-62.93%
1-Tages-Spanne:
Value
$8.59
$8.8868
1-Wochen-Bereich:
Value
$7.91
$9.0702
52-Wochen-Spanne:
Value
$6.10
$28.67

Bicycle Therapeutics Plc Adr Stock (BCYC) Company Profile

Name
Firmenname
Bicycle Therapeutics Plc Adr
Name
Telefon
011441223261503
Name
Adresse
BLOCKS A & B, PORTWAY BUILDING, CAMBRIDGE
Name
Mitarbeiter
305
Name
Twitter
@Bicycle_tx
Name
Nächster Verdiensttermin
2024-10-31
Name
Neueste SEC-Einreichungen
Name
BCYC's Discussions on Twitter

Vergleichen Sie BCYC mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
BCYC
Bicycle Therapeutics Plc Adr
8.725 579.66M 36.90M -166.28M -203.53M -3.29
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
475.19 120.73B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
571.92 60.56B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
331.46 42.41B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
589.03 34.96B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
296.04 31.99B 3.81B -644.79M -669.77M -6.24

Bicycle Therapeutics Plc Adr Stock (BCYC) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2024-11-08 Eingeleitet Stephens Equal-Weight
2024-09-06 Eingeleitet RBC Capital Mkts Outperform
2024-08-07 Herabstufung B. Riley Securities Buy → Neutral
2023-09-11 Hochstufung B. Riley Securities Neutral → Buy
2022-08-31 Eingeleitet Cowen Outperform
2022-07-28 Eingeleitet Barclays Overweight
2022-07-06 Fortgesetzt Canaccord Genuity Buy
2022-04-13 Herabstufung B. Riley Securities Buy → Neutral
2022-04-07 Fortgesetzt Cantor Fitzgerald Overweight
2022-02-14 Eingeleitet Morgan Stanley Equal-Weight
2021-12-17 Eingeleitet SVB Leerink Outperform
2021-12-09 Eingeleitet Needham Buy
2021-09-30 Eingeleitet B. Riley Securities Buy
2021-04-20 Eingeleitet JMP Securities Mkt Outperform
2020-10-12 Eingeleitet Cantor Fitzgerald Overweight
2020-06-12 Eingeleitet Oppenheimer Outperform
2020-04-17 Eingeleitet H.C. Wainwright Buy
2019-11-14 Eingeleitet ROTH Capital Buy
2019-09-11 Hochstufung Goldman Neutral → Buy
2019-06-17 Eingeleitet Canaccord Genuity Buy
2019-06-17 Eingeleitet Goldman Neutral
2019-06-17 Eingeleitet Jefferies Buy
2019-06-17 Eingeleitet Piper Jaffray Overweight
Alle ansehen

Bicycle Therapeutics Plc Adr Aktie (BCYC) Neueste Nachrichten

pulisher
Jul 17, 2025

Amicus Therapeutics, Inc. (NASDAQ:FOLD) Shares Sold by Teacher Retirement System of Texas - Defense World

Jul 17, 2025
pulisher
Jul 17, 2025

Principal Financial Group Inc. Boosts Stock Position in Schneider National, Inc. (NYSE:SNDR) - Defense World

Jul 17, 2025
pulisher
Jul 17, 2025

Principal Financial Group Inc. Purchases 1,695 Shares of Monarch Casino & Resort, Inc. (NASDAQ:MCRI) - Defense World

Jul 17, 2025
pulisher
Jul 17, 2025

Teacher Retirement System of Texas Has $465,000 Stake in Beam Therapeutics Inc. (NASDAQ:BEAM) - Defense World

Jul 17, 2025
pulisher
Jul 17, 2025

Teacher Retirement System of Texas Sells 1,266 Shares of Akero Therapeutics, Inc. (NASDAQ:AKRO) - Defense World

Jul 17, 2025
pulisher
Jul 17, 2025

Teacher Retirement System of Texas Has $534,000 Holdings in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) - Defense World

Jul 17, 2025
pulisher
Jul 17, 2025

William Blair Brokers Decrease Earnings Estimates for TLX - Defense World

Jul 17, 2025
pulisher
Jul 17, 2025

Principal Financial Group Inc. Boosts Stake in Capri Holdings Limited (NYSE:CPRI) - Defense World

Jul 17, 2025
pulisher
Jul 17, 2025

First Northwest Bancorp (FNWB) Expected to Announce Quarterly Earnings on Thursday - Defense World

Jul 17, 2025
pulisher
Jul 04, 2025

The Bank of Nova Scotia (TSE:BNS) Receives Average Rating of “Hold” from Analysts - Defense World

Jul 04, 2025
pulisher
Jun 22, 2025

Bicycle Therapeutics (NASDAQ:BCYC) Shares Gap Up – Should You Buy? - Defense World

Jun 22, 2025
pulisher
May 26, 2025

Bicycle Therapeutics’ SWOT analysis: stock faces pivotal phase amid clinical progress - Investing.com India

May 26, 2025
pulisher
May 07, 2025

Market Update: Bicycle Therapeutics Plc ADR (BCYC) Sees Negative Movement, Closing at 7.40 - DWinneX

May 07, 2025
pulisher
May 01, 2025

Bicycle Therapeutics earnings missed by $0.03, revenue topped estimates - Investing.com South Africa

May 01, 2025
pulisher
Apr 24, 2025

How should investors view Bicycle Therapeutics Plc ADR (BCYC)? - uspostnews.com

Apr 24, 2025
pulisher
Apr 24, 2025

PBF Energy Inc [PBF] Records 50-Day SMA of $19.79 - knoxdaily.com

Apr 24, 2025
pulisher
Apr 24, 2025

UGI Corp [UGI] Records 200-Day SMA of $27.63 - knoxdaily.com

Apr 24, 2025
pulisher
Apr 24, 2025

Cellebrite DI Ltd [NASDAQ: CLBT] Sees Increase in Stock Value - knoxdaily.com

Apr 24, 2025
pulisher
Apr 24, 2025

Bicycle Therapeutics Plc ADR [BCYC] Shares Fall -0.69 % on Wednesday - knoxdaily.com

Apr 24, 2025
pulisher
Apr 23, 2025

European Equities Traded in the US as American Depositary Receipts Rise Sharply in Tuesday Trading - MSN

Apr 23, 2025
pulisher
Apr 23, 2025

Bicycle Therapeutics Plc ADR Inc. (BCYC) Price Performance: The Role of Supply and Demand - investchronicle.com

Apr 23, 2025
pulisher
Apr 07, 2025

Fastenal Co (FAST) may enjoy gains as insiders got busy in the recent days - knoxdaily.com

Apr 07, 2025
pulisher
Apr 05, 2025

Bicycle therapeutics CFO Alethia Young sells $1,724 in stock By Investing.com - Investing.com India

Apr 05, 2025
pulisher
Apr 04, 2025

Bicycle therapeutics CTO Michael Skynner sells shares worth $14,292 By Investing.com - Investing.com South Africa

Apr 04, 2025
pulisher
Apr 04, 2025

Bicycle therapeutics COO Alistair Milnes sells $16,850 in stock By Investing.com - Investing.com South Africa

Apr 04, 2025
pulisher
Apr 04, 2025

Bicycle Therapeutics chief product officer sells shares worth $5,735 - Investing.com

Apr 04, 2025
pulisher
Apr 04, 2025

Bicycle Therapeutics CEO Lee Kevin sells shares worth $43,612 - Investing.com

Apr 04, 2025
pulisher
Apr 04, 2025

Bicycle Therapeutics chief accounting officer sells shares worth $2,499 - Investing.com

Apr 04, 2025
pulisher
Apr 04, 2025

Bicycle therapeutics CFO Alethia Young sells $1,724 in stock - Investing.com

Apr 04, 2025
pulisher
Apr 04, 2025

Bicycle therapeutics CTO Michael Skynner sells shares worth $14,292 - Investing.com

Apr 04, 2025
pulisher
Apr 04, 2025

Bicycle Therapeutics chief accounting officer sells shares worth $2,499 By Investing.com - Investing.com UK

Apr 04, 2025
pulisher
Mar 31, 2025

Bicycle Therapeutics stock hits 52-week low at $8.6 amid downturn By Investing.com - Investing.com South Africa

Mar 31, 2025
pulisher
Mar 27, 2025

Bicycle Therapeutics reshuffles leadership, aims for oncology advances By Investing.com - Investing.com South Africa

Mar 27, 2025
pulisher
Mar 27, 2025

Bicycle Therapeutics reshuffles leadership, aims for oncology advances - Investing.com India

Mar 27, 2025
pulisher
Mar 24, 2025

Bicycle Therapeutics stock hits 52-week low at $8.98 By Investing.com - Investing.com South Africa

Mar 24, 2025
pulisher
Mar 12, 2025

Bicycle Therapeutics’ SWOT analysis: innovative platform drives stock potential - Investing.com India

Mar 12, 2025
pulisher
Mar 03, 2025

Advanced Urothelial Carcinoma Clinical Trial Pipeline Analysis Demonstrates 20+ Key Companies at the Horizon Expected to Transform the Treatment Paradigm, Assesses DelveInsight - GlobeNewswire Inc.

Mar 03, 2025
pulisher
Feb 25, 2025

Jefferies cuts Bicycle Therapeutics price target to $42 from $53 By Investing.com - Investing.com South Africa

Feb 25, 2025
pulisher
Feb 25, 2025

Bicycle Therapeutics stock holds $33 target, Buy rating at Rodman By Investing.com - Investing.com South Africa

Feb 25, 2025
pulisher
Feb 25, 2025

Mizuho maintains Harmony Biosciences $42 target, Outperform rating - Investing.com India

Feb 25, 2025
pulisher
Feb 25, 2025

Mizuho maintains Harmony Biosciences $42 target, Outperform rating By Investing.com - Investing.com South Africa

Feb 25, 2025
pulisher
Jan 15, 2025

Bicycle Therapeutics' SWOT analysis: platform potential drives stock outlook - Investing.com India

Jan 15, 2025
pulisher
Jan 13, 2025

Bicycle Therapeutics reports promising cancer drug trial results - Investing.com

Jan 13, 2025
pulisher
Jan 06, 2025

Bicycle Therapeutics exec sells $30k in shares - Investing.com

Jan 06, 2025
pulisher
Oct 23, 2024

Bicycle Therapeutics spotlights cancer treatment targets - Investing.com

Oct 23, 2024
pulisher
Oct 14, 2024

Bicycle Therapeutics (BCYC) Soars 5.7%: Is Further Upside Left in the Stock? - Yahoo Finance

Oct 14, 2024
pulisher
Oct 07, 2024

Oppenheimer backs Bicycle Therapeutics' BRC platform, reiterates $48 stock PT - Investing.com UK

Oct 07, 2024
pulisher
Oct 04, 2024

Bicycle therapeutics CEO sells shares worth over $71k - Investing.com

Oct 04, 2024
pulisher
Aug 10, 2024

Europe Peptide Drug Conjugates Market Size & Outlook, 2030 - Grand View Research

Aug 10, 2024
pulisher
Jul 14, 2024

South Korea Peptide Drug Conjugates Market Size & Outlook, 2030 - Grand View Research

Jul 14, 2024
pulisher
Jun 21, 2024

Top 5 Small-Cap Biotechnology Stocks for a Stable Portfolio - Nasdaq

Jun 21, 2024

Finanzdaten der Bicycle Therapeutics Plc Adr-Aktie (BCYC)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading

Bicycle Therapeutics Plc Adr-Aktie (BCYC) Insiderhandel

Insiderhandel Beziehung Datum Transaktion Kosten #Aktien Wert ($) #Aktien Gesamt
Lee Kevin
CHIEF EXECUTIVE OFFICER
Jul 02 '25
Sale
7.09
2,268
16,080
483,997
Skynner Michael
CHIEF TECHNOLOGY OFFICER
Jul 03 '25
Sale
7.44
966
7,187
120,079
Skynner Michael
CHIEF TECHNOLOGY OFFICER
Jul 02 '25
Sale
7.09
825
5,849
121,045
Milnes Alistair
CHIEF OPERATING OFFICER
Jul 02 '25
Sale
7.09
1,149
8,146
96,468
Milnes Alistair
CHIEF OPERATING OFFICER
Jul 03 '25
Sale
7.44
966
7,187
95,502
Hannay Michael Charles Ferguso
CHIEF PROD & SUPPLY CHAIN OFF
Jul 02 '25
Sale
7.09
474
3,361
54,073
Hannay Michael Charles Ferguso
CHIEF PROD & SUPPLY CHAIN OFF
Jul 03 '25
Sale
7.44
248
1,845
53,825
Thompson Travis Alvin
CHIEF ACCOUNTING OFFICER
Jul 02 '25
Sale
7.09
206
1,461
31,621
Thompson Travis Alvin
CHIEF ACCOUNTING OFFICER
Jul 03 '25
Sale
7.44
100
744
31,521
Young Alethia
Chief Financial Officer
Jul 02 '25
Sale
7.09
204
1,446
45,186
$23.62
price up icon 3.26%
$36.56
price up icon 1.51%
$103.38
price down icon 0.14%
$27.57
price down icon 1.58%
$114.12
price down icon 0.42%
biotechnology ONC
$296.06
price up icon 0.42%
Kapitalisierung:     |  Volumen (24h):